Alcohol alternatives
Intro to a Deep Research series
I recently realized that over the past few weeks I’ve actually spent almost as much time reading outputs from LLM Deep Research as I have on Substack, Twitter, scientific papers, or news sources. It’s just so addicting to be able to read in-depth articles tailored exactly to whatever whim your curiosity leads you to at that moment.
I’ve found a few of these outputs so interesting that I thought I would post them here, also as a lazy way to get this Substack going while I grind out my very slow, human-generated posts in the background.
I’ve cut out some boring sections as well as my follow-up prompts, but the entirety of the answers are AI generated. Please note that this is just for fun and I have done zero fact-checking.
Enjoy!
Could there be a replacement compound for alcohol that produces the same effect with less toxicity?
o1 pro, researched for 7m 11s, 26 sources
Potential Ethanol Replacements for Recreational Use
Introduction
Ethanol (beverage alcohol) produces relaxation, euphoria, and sociability but at the cost of significant toxicity. Chronic alcohol use can damage the liver, brain, heart, and other organs, and alcohol is implicated in millions of deaths worldwide . It is rated as one of the most harmful commonly used drugs . The search is on for alternative psychoactive compounds that deliver the desirable effects of alcohol without its health downsides . An ideal alternative would be orally active, produce similar anxiolytic and social effects (via comparable neurotransmitter pathways), but have reduced toxicity (no liver injury or neurodegeneration) and lower addiction potential. Below we review leading candidates – both known drugs and experimental molecules – including their mechanisms of action, pharmacology compared to ethanol, safety profiles, and development status.
How Alcohol Works (Key Effects to Mimic)
Ethanol is a small, amphiphilic molecule that diffuses throughout the body and brain . Its pharmacodynamic effects are complex: at low doses it releases dopamine (producing mild euphoria) and acts as a positive modulator of GABA_A receptors (inhibitory) while inhibiting NMDA glutamate receptors . Together this causes anxiolysis, disinhibition, and relaxation, the sought-after “buzz.” At higher doses, ethanol more strongly potentiates GABA_A and glycine receptors and further blocks NMDA, leading to sedation, motor impairment, and amnesia. The undesired toxic effects of ethanol result partly from its metabolism (e.g. acetaldehyde-induced oxidative stress) and from its broad actions on the brain (causing dependence and neuroadaptation). Any replacement compound will likely target the same pathways (especially GABA) for similar subjective effects , but ideally more selectively to avoid toxic byproducts and excessive sedation. Below we categorize candidate compounds by their primary mechanisms.
GABAergic Alternatives (GABA Receptor Modulators)
Many alcohol-like effects come from enhancing GABA, the brain’s main inhibitory neurotransmitter. Ethanol enhances GABA_A receptor activity (especially via receptors containing certain subunits) and also increases GABA release. Thus, GABA receptor modulators are prime candidates to replicate alcohol’s relaxing and sociable effects .
Alcarelle (“Alcosynth”) – Synthetic GABA_A Modulator
One of the most prominent efforts is Alcarelle, a code name for a synthetic molecule being developed by GABA Labs (co-founded by Prof. David Nutt) as a direct alcohol replacement . Alcarelle is a positive allosteric modulator (PAM) of GABA_A receptors – much like ethanol and benzodiazepines – but is designed to be a partial modulator with a built-in “ceiling effect.” This means beyond a certain dose it won’t produce greater GABA activation, preventing extreme intoxication or respiratory depression . According to Nutt, the team synthesized over 30 candidate molecules and narrowed to four lead compounds meeting key criteria: (1) Effective anxiolytic action (enhancing GABA’s calming effect) without pushing into deep sedation , (2) Fast oral absorption for a quick onset akin to drinking alcohol, and (3) Rapid clearance to avoid lingering effects or hangovers . Importantly, the compound is designed to not significantly interact with other neurotransmitter systems (unlike ethanol which hits many targets) , thereby reducing side effects.
Early reports indicate Alcarelle’s effects would mimic the mild relaxation of a drink or two – promoting sociability and reducing anxiety – but without impairing motor function or cognition to the same degree and without the dehydration and acetaldehyde-related hangover . Because it is a novel food-grade ingredient, it is going through safety testing for regulatory approval as a beverage additive (seeking “GRAS” status in the US) rather than as a drug . As of 2024, GABA Labs anticipated entering FDA/UK novel food approval by 2024, aiming for market release by ~2026 . The exact chemical identity of Alcarelle is under wraps (patents were filed under “mood enhancing compounds”) , but it is described as a small molecule targeting a specific GABA_A receptor site distinct from alcohol’s binding site . If successful, Alcarelle could be mixed into non-alcoholic beers, wines, or cocktails to provide a “functional drink” that delivers convivial effects without ethanol .
Mechanism & Pharmacology: GABA_A partial PAM (likely selective for subunits associated with anxiolysis). Fast-acting and fast-clearing by design . Intended to produce mild euphoria, relaxation, and social disinhibition at low “doses,” with a built-in limit to prevent severe intoxication . No acetaldehyde production (unlike ethanol), so no direct liver toxicity or hangover from metabolites is expected.
Safety & Status: Preclinical testing underway; not yet tested in full human trials as of 2025. Anticipated to have a much higher safety margin than ethanol – e.g. causing far less impairment per unit of effect . Because it’s a GABA_A PAM, there is still a possibility of some withdrawal or tolerance with heavy use (as with any GABAergic), but the developers aim to minimize this by avoiding the high receptor occupancy that causes dependence . Alcarelle will be sold as an ingredient (not directly to consumers) licensed to beverage makers worldwide if it gains approval. This effort is at the forefront of synthetic alcohol substitutes.
Benzodiazepines and Novel GABA_A Subtype Modulators
Conventional benzodiazepine drugs (e.g. diazepam, lorazepam) have long been noted to produce effects overlapping with alcohol: anxiolysis, sedation, and muscle relaxation. In fact, a benzodiazepine like lorazepam can produce alcohol-like intoxication in humans . These drugs act as non-selective GABA_A receptor PAMs (binding the benzodiazepine site on many subtypes of the receptor), broadly boosting inhibition. While they lack ethanol’s organ toxicity, they come with their own risks – notably dependence and withdrawal (which can be as dangerous as alcohol withdrawal) and memory impairment. Benzos do not cause liver damage or brain cell loss directly, making them less physically toxic than alcohol, but their addiction liability and overdose risk (especially when combined with alcohol or opioids) are significant. For these reasons, traditional benzodiazepines are not an ideal replacement for recreational use. They are, however, sometimes used by individuals as a substitute (for example, people with alcohol use disorder may use benzodiazepines to stave off withdrawal or mimic alcohol’s anxiety relief).
Next-generation GABA_A modulators have been developed to try to separate the desirable effects from the undesirable. Certain GABA_A receptor subtypes are linked more to anxiolytic, rewarding effects (e.g. α2, α3 subunits), while others (like α1) are linked to strong sedation and reinforcement . Drug designers have created subtype-selective GABA_A PAMs and partial agonists:
Z-drugs (zolpidem, zopiclone) – selective for α1 subunits – cause sedation (hence used as sleep aids). In daytime, they can feel similar to alcohol (dizziness, “drunk” feeling) and indeed are abused recreationally by some, but they carry risk of dependence and odd behaviors . Their selectivity actually hits the α1-mediated reinforcing pathway strongly (α1 is implicated in the pleasurable/reinforcing effect of alcohol) , so Z-drugs are not safer in terms of abuse potential.
α2/α3-selective modulators – these aim for anti-anxiety effects without heavy sedation. An example was AZD7325, a partial modulator preferring α2/α3 GABA_A receptors. In a clinical trial it produced some alcohol-like subjective effects (e.g. relaxation, mild euphoria) at certain doses , but with less sedation than classical benzodiazepines. Such compounds could in theory provide the social anxiety relief of alcohol without as much motor impairment. However, development is challenging; AZD7325’s clinical results were modest and it did not reach market. Another compound, ocinaplon, was a partial GABA_A agonist that showed anxiolytic effects with minimal sedation in early trials, but was discontinued after rare cases of elevated liver enzymes (a toxicity unrelated to its intended mechanism).
Neurosteroid analogs – compounds like brexanolone and ganaxolone modulate GABA_A at the neurosteroid site. These can produce deep calm and sedation. They are being developed for depression and epilepsy, not specifically for recreation. While effective anxiolytics, they can be sedating at higher doses and haven’t been tested as “alcohol substitutes.”
In summary, benzodiazepine-like compounds confirm that targeting GABA_A can replicate much of alcohol’s subjective effect . They are less acutely toxic to organs (no acetaldehyde, no direct organ damage), but they can be addictive and cause severe withdrawal with prolonged use. Novel selective PAMs offer promise of lower abuse potential – e.g. a compound that avoids the α1 subtype might cause less dopamine-mediated euphoria and thus less dependence . Any such drug would need to be proven safe for non-prescription use. Currently, no selective GABA_A modulators are approved for recreational use, but research in this area (often for new anxiety medications) may yield a future “benzo-like social drug” with a better safety profile.
GABA_B Receptor Agonists (Baclofen, Phenibut, GHB)
Alcohol also indirectly affects the GABA_B receptor system. GABA_B receptors (metabotropic GABA receptors) produce a slower form of inhibition. The drug γ-hydroxybutyrate (GHB), and the medications baclofen and phenibut, all activate GABA_B receptors and have been used to replicate some of alcohol’s effects.
GHB (γ-hydroxybutyrate): GHB is a naturally occurring compound and a GABA_B agonist (it also binds its own GHB-specific receptors). Pharmacologically, GHB is a CNS depressant with effects very similar to alcohol – at low doses it causes euphoria, sociability, relaxation, and disinhibition, while higher doses lead to sedation or sleep . Many users describe GHB’s intoxicating effect as “like alcohol without the hangover.” Notably, GHB is used medically (sodium oxybate) in treating narcolepsy and in some countries to treat alcohol withdrawal or dependence (by substituting for alcohol) . GHB does not produce toxic metabolites and does not damage the liver – it’s largely metabolized to carbon dioxide and water. However, GHB’s safety issues lie in its narrow dosing margin: the difference between an enjoyable dose and a dangerous dose is small. Overdose can cause deep unconsciousness and respiratory depression. It’s also notoriously associated with drug-facilitated assault (“date rape drug”) due to sedation at high doses. Repeated use of GHB can cause dependence; withdrawal symptoms (insomnia, anxiety, tremors) can be severe, akin to alcohol or benzodiazepine withdrawal. GHB is a controlled substance (Schedule I in the US, except the prescription formulation). While it demonstrates that pure GABA_B agonism can mimic ethanol’s prosocial and euphoric effects , its abuse potential and overdose risk make it a problematic “replacement.” Researchers are studying safer GHB analogs or dosing strategies; for example, controlled oral doses under supervision can treat alcoholism by substituting GHB for alcohol then tapering . But for general recreational use, GHB remains high-risk despite low organ toxicity.
Phenibut: Phenibut (β-phenyl-GABA) is a GABA_B agonist (and weak GABA_A agonist) developed in the Soviet Union. It has anxiolytic and mild mood-brightening properties. Phenibut is not approved in most Western countries but is sold as a supplement online. Users report that at recreational doses (e.g. 1–2 grams), phenibut produces calm euphoria, reduced social inhibition, and relaxation similar to alcohol’s effects but usually without motor impairment. It was even nicknamed a “party powder” by some communities. Phenibut’s pharmacokinetics differ from alcohol: it’s a powder/pill that takes 2–4 hours to kick in (slower onset), and effects can last 8–24 hours depending on dose (long duration). It does not cause a hangover in the sense of dehydration or acetaldehyde toxicity, and it’s not directly hepatotoxic. However, phenibut can cause dependence. Regular use leads to tolerance, requiring higher doses for effect, and abrupt cessation can result in withdrawal symptoms (anxiety, insomnia, possibly seizures in severe cases) . In Russia, phenibut is actually given to treat alcohol withdrawal and anxiety , indicating some cross-tolerance with ethanol. Recreationally, it’s been responsible for emergency room visits when taken in huge excess or combined with other depressants. The toxicity profile of phenibut is otherwise fairly benign (no organ damage), but overdose can cause vomiting, lowered consciousness, and in combination with alcohol or sedatives it’s dangerous. Phenibut is currently uncontrolled in the US (though the FDA has barred its sale in dietary supplements), and it remains an accessible though risky self-medicated alcohol substitute. It exemplifies that GABA_B agonists can provide ethanol-like anxiolysis and social ease, but with significant dependence liability if misused.
Baclofen: Baclofen is a prescription GABA_B agonist (used as a muscle relaxant). Some clinical trials and anecdotal reports have used high-dose baclofen to treat alcohol dependence – it can reduce alcohol cravings and mimic some effects of alcohol, helping people abstain . Baclofen can produce relaxation and a sense of well-being in some individuals, but it also commonly causes drowsiness and dizziness. It is not commonly abused recreationally, perhaps because its euphoric effect is mild. Still, baclofen shares the trait of no direct organ toxicity, and in theory someone could use baclofen instead of alcohol to relieve anxiety. Tolerance and physical dependence can occur if baclofen is taken continuously at high doses, and sudden withdrawal can be dangerous (including seizures). Baclofen is not a mainstream “alternative intoxicant” but is relevant as a tool in alcohol addiction treatment (a harm-reduction medication).
Summary (GABA_B agents): These compounds show that stimulating GABA_B receptors can partially stand in for alcohol – particularly for the sedative and anti-anxiety aspects. They generally do not cause the kind of long-term physical harm ethanol does (no cirrhosis, etc.), but all can cause CNS depression and have addiction potential. GHB and phenibut in particular demonstrate a recreational following. From a pharmacokinetic perspective, these are longer-acting than ethanol (except GHB which has a short 30min–3h effect window depending on dose). That can be a downside if one is “intoxicated” for too long. On the plus side, they lack ethanol’s metabolic byproducts that cause hangovers; for example, pure GHB use typically does not produce a hangover (aside from perhaps sleepiness after-effects). Nonetheless, due to legal control and safety issues, GABA_B agonists are imperfect ethanol replacements. Researchers continue to investigate if modulating GABA_B more subtly (perhaps through positive allosteric modulators rather than direct agonists) could yield a gentler alcohol-mimetic with less risk.
Gabapentinoids (Pregabalin and Gabapentin)
Another class sometimes mentioned as “alcohol substitutes” are the gabapentinoids, specifically pregabalin (Lyrica) and gabapentin (Neurontin). These are prescription drugs for epilepsy, neuropathic pain, and (in Europe) anxiety, but they have also seen off-label use in treating alcohol withdrawal and even recreational use.
Gabapentinoids do not bind GABA receptors directly; instead, they bind to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release . The net effect is a CNS depressant-like action. Users report that pregabalin in particular produces a state akin to intoxication: it can cause dizziness, warmth, relaxed euphoria, and sociability. In fact, some recreational users call pregabalin “Budweisers” on the street, referring to its alcohol-mimicking buzz . One study noted that abusers considered pregabalin an “ideal psychotropic” producing effects similar to alcohol, GHB, or benzodiazepines – including entactogenic (empathy-enhancing) feelings and even mild dissociation at high doses . Importantly, pregabalin is orally active (taken as pills), and while its onset is slower than alcohol (peak in ~1 hour), its effects can last 4–6 hours, somewhat comparable to a long evening of drinking. It is metabolized by the kidneys (minimal liver metabolism), so it does not stress the liver or other organs. Pregabalin overdoses in isolation are usually not fatal – studies indicate that even large doses primarily cause sedation or ataxia, but do not suppress breathing or heart function severely . This suggests a wider safety margin in overdose than ethanol (which at very high blood levels can certainly shut down breathing). However, combining pregabalin with other depressants (including alcohol) is dangerous and has led to fatal outcomes . Gabapentin is similar but generally considered less potent in its intoxicating effects.
From a toxicology standpoint, gabapentinoids have no known neurotoxic or hepatotoxic effects. The main risk is dependence and withdrawal if abused. Tolerance can develop, and some patients experience withdrawal symptoms (anxiety, insomnia) after high-dose prolonged use of pregabalin. Pregabalin is a Schedule V controlled substance in the US and a Class C controlled drug in the UK due to rising abuse. It is approved (in EU) for generalized anxiety disorder, which speaks to its calming effects. Some clinicians have even tried using gabapentin or pregabalin to help recovering alcoholics by easing protracted withdrawal anxiety or reducing cravings, though results vary.
In summary, pregabalin can serve as a pharmacological substitute to mimic alcohol’s relaxed, sociable feeling . It lacks the organ toxicity of ethanol and is relatively safe in overdose by itself . But it is habit-forming and not risk-free – it should be regarded as a prescription drug with abuse potential rather than a benign over-the-counter alternative. Nonetheless, its profile (oral effectiveness, anxiolysis, mild euphoria) makes it a notable candidate in discussions of safer alcohol replacements.
(Note: Another gabapentinoid-like drug, valproate, a mood stabilizer, also increases GABA levels but is not used for intoxication and can have its own liver toxicity, so it’s not considered here as an alcohol alternative.)
Serotonergic/Dopaminergic Euphoriants
While GABA-targeting compounds mimic alcohol’s relaxation and anxiolysis, alcohol’s mood-lifting and social stimulation also involve dopamine and serotonin. Some researchers have explored compounds that act via monoamine neurotransmitters (serotonin, dopamine, etc.) to produce a different route to sociability and euphoria without alcohol’s toxic metabolism.
MEAI (5-Methoxy-2-aminoindane)
A very interesting novel compound is MEAI, a serotonergic agent that has been touted as a possible “alcohol substitute.” MEAI was originally used recreationally (circa 2010s) as a legal party drug in some circles, and users noticed it produced alcohol-like positive effects and even reduced their desire to drink further . Now, an Israeli-Canadian biotech company (Clearmind Medicine) is developing MEAI as a treatment for alcohol use disorder (calling it CMND-100) , leveraging its unique dual action: mild euphoria plus reduced alcohol craving.
Mechanistically, MEAI is a monoamine releasing agent with a preference for releasing serotonin (5-HT) over dopamine or norepinephrine . In vitro, it has about a 20:1 selectivity for inducing serotonin release vs dopamine release . This profile is somewhat analogous to a very gentler form of MDMA (Ecstasy), which might explain reports of entactogenic effects (feelings of social connection and well-being) without a strong stimulant high . By releasing serotonin, MEAI can elevate mood and relax inhibitions. It also has moderate affinity for α2-adrenergic receptors , which could contribute to relaxation (α2 activation can reduce anxiety by inhibiting norepinephrine release). The net effect as described by users and early studies is a “buzz” with a clear head: a feeling of happiness, warmth, and sociability akin to a couple of drinks, but without slurred speech or loss of motor control. Importantly, many users did not feel the urge to keep re-dosing or binge, unlike with alcohol where one often craves more . This hints that MEAI might have a built-in satiety mechanism for reward – possibly through serotonin’s role in satisfaction.
In terms of toxicity, MEAI is still under investigation. Chemically, it’s an aminoindane (a ring-based analog of amphetamines). Unlike MDMA, it is less potent in releasing dopamine, so theoretically it should be less neurotoxic to serotonin neurons (since serotonin neurotoxicity is linked to excessive dopamine and oxidative stress in those nerve terminals). Animal studies so far (Clearmind reports in mice) have shown reduced alcohol consumption and no obvious physiological harm, but full toxicology studies are ongoing. One peer-reviewed paper in 2017 by David Nutt and colleagues detailed MEAI’s metabolism and effects, finding it has a reasonably clean profile . We should note that any serotonin-releasing drug carries a risk of serotonin syndrome (if combined with other serotonergics) and possibly neuroadaptation if abused frequently. However, MEAI’s proponents argue its “misuse liability” is lower than classic stimulants . Early human self-reports did not show compulsive redosing – in fact, some said it deters over-drinking .
MEAI is currently experimental: Clearmind has patents and is conducting preclinical studies, with plans for clinical trials. It is not an approved substance; if anything, it might eventually be a prescription medication for alcoholism. But as a concept, MEAI represents a non-GABAergic path to mimic alcohol’s sociability. By inducing serotonin release, it produces mood elevation, empathy, and relaxation (somewhat like a very mild roll from MDMA) without directly depressing the central nervous system or producing toxic metabolites . It’s an intriguing approach because it targets the reward circuitry (serotonin/dopamine) rather than the inhibitory circuitry (GABA) that alcohol affects. A potential downside is that it might not address the physical relaxation that GABAergic drugs provide – MEAI users may feel energized or normal rather than sedated. This could be a benefit (no drowsiness), but someone seeking the muscle-relaxant “loose” feeling of alcohol might not get it from MEAI.
In summary, MEAI shows promise as a euphoric, non-toxic alternative – providing a “happy drunk” sensation while possibly reducing the drive to consume more . More research is needed on safety (long-term effects on the brain’s serotonin system, etc.). If it proves safe, it could become a controlled therapeutic or even a regulated recreational product. It underscores the possibility of novel psychoactives that break the mold of how we achieve social euphoria.
Empathogens and Stimulants (MDMA, etc.)–an aside
Compounds like MDMA (Ecstasy) or related entactogens (e.g. 6-APB, methylone) are known for producing intense euphoria, empathy, and sociability. In a sense, they can replace alcohol’s social effect (some people prefer taking MDMA at parties instead of drinking). They do not mimic alcohol’s mechanism (MDMA causes massive serotonin and dopamine release) and thus have very different side effects profile: dehydration risk, possible neurotoxicity to serotonin neurons with heavy use, and a comedown or depression the next day as neurotransmitters deplete. These drugs are also illegal (Schedule I in most places). While MDMA and its cousins are powerfully pro-social, they are far from a safe alcohol replacement for regular use. They are typically viewed as occasional party drugs, not something one would consume like a few beers after work due to their intensity and after-effects.
One interesting note: small doses of stimulants (like low-dose amphetamine) can produce sociability, but they tend to increase anxiety for many and don’t have the calming aspect of alcohol. Thus, pure stimulants are not a good substitute for the relaxing component of alcohol’s effect.
Cannabinoids (Cannabis, CBD)
Cannabis has emerged as a popular alternative to alcohol for many, especially in places where it’s legal. Δ⁹-THC, the active component in marijuana, acts on CB1 cannabinoid receptors to produce relaxation, altered perception, and euphoria. A low or moderate dose of THC (for instance, an edible or a few puffs) can make users more sociable and euphoric, potentially serving the same social lubricant role as a drink. Cannabis does not cause the organ damage that alcohol does – no liver toxicity (in fact, some evidence suggests cannabinoids are anti-inflammatory for the liver), and no lethal overdose risk in terms of respiratory depression. However, cannabis has its own downsides: it impairs cognition and reaction time, which can affect driving or work performance similar to or worse than alcohol in some cases. It also can cause anxiety or paranoia in some users, the opposite of alcohol’s anxiolytic effect. Regular heavy use of cannabis can lead to dependence and cognitive effects (though generally less severe than alcohol dependence). Some people use CBD (cannabidiol), a non-intoxicating component of cannabis, for anxiety relief as an alcohol alternative – but CBD alone doesn’t produce a “buzz” or euphoria, just a subtle calming. In summary, cannabis/THC is a readily available recreational alternative that eliminates alcohol’s physical toxicity, but it differs qualitatively in effect and comes with its own safety considerations. It might be considered a partial substitute (more relaxing than stimulating) and indeed cannabis-infused beverages are an emerging market for those who want a “session” drink without alcohol. Still, because cannabis is a controlled substance and can impair functions and in some cases promote overeating or anxiety, it’s not a perfect ethanol replacement for everyone.
Kava (Piper methysticum)–a Natural Alternative
When looking to nature for alcohol alternatives, kava is one of the most notable traditional examples. Kava is a drink made from the roots of the Piper methysticum plant (native to the South Pacific). For millennia, Pacific Islanders have used kava as a social and ceremonial beverage in place of alcohol . Kava’s active compounds, called kavalactones (such as kavain, dihydrokavain, methysticin, etc.), produce effects of relaxation, elevated mood, and sociability. Notably, kava tends to calm without clouding the mind as much – users often feel tranquil and sociable yet clear-headed. It has even been observed to reduce aggression compared to alcohol , making for a more mellow social atmosphere.
Mechanistically, kavalactones modulate GABA_A receptors (though not at the benzodiazepine site) . Kavain, the major kavalactone, has been shown to positively modulate GABA_A receptors across multiple subtypes, especially the extrasynaptic δ-containing receptors (which may contribute to a deep calm) . This GABAergic action likely underlies kava’s anxiolytic (anti-anxiety) effect. Additionally, kavalactones can block certain sodium and calcium ion channels and modulate dopamine pathways slightly, contributing to muscle relaxation and mild euphoria. Pharmacokinetically, kavalactones are lipophilic and absorb over about 20–30 minutes from a kava drink, with effects lasting a couple of hours (depending on potency and dose). This roughly parallels the onset and duration of moderate alcohol intake, although heavy kava drinking can have longer-lasting effects due to cumulative dosing.
Toxicology and safety: Unlike ethanol, kavalactones are not directly toxic to the liver in moderate doses. However, there was controversy: in the early 2000s, cases of severe liver injury were reported in people using kava extracts, leading to bans in Europe. Later reviews found that these cases were rare and possibly linked to improper kava preparation or co-medications . Kava products sometimes used stems or leaves (which contain alkaloids like pipermethystine that may be hepatotoxic ) or organic solvents in extracts, which could have contributed. Traditional aqueous kava (made from root powder with water) appears much safer, and subsequent analyses and WHO reviews found a positive benefit-to-risk ratio for kava when used correctly . Today, kava is legal in the US and many countries (sometimes as a dietary supplement for anxiety). Regular heavy kava use can lead to a reversible skin rash/itch (kava dermopathy) and possible weight loss, but doesn’t cause permanent organ damage in the way alcohol can. Kava also does not seem to cause significant tolerance or dependence – daily users in the South Pacific don’t exhibit a severe withdrawal syndrome when they stop, beyond maybe psychological craving. That said, any sedative used to alleviate anxiety could become habit-forming psychologically.
Because of its oral availability and calming yet uplifting effects, kava has gained popularity globally as an alcohol alternative. Kava bars now exist in many Western cities, serving kava drinks as a substitute for cocktails or beers. Patrons can socialize and relax without getting drunk. Many describe the kava experience as “a relaxed buzz without impairment”. Motor coordination is relatively preserved (though high doses can cause some unsteadiness or drowsiness). Crucially, kava does not make people aggressive – in fact, it’s noted for inducing a tranquil, friendly state . This could have public health benefits if adopted more widely: fewer fights, accidents, and health harms.
However, kava’s psychoactive strength is lower than alcohol for many people. Some might find it too subtle or dislike its taste (muddy, earthy). There’s also a limit to how much kava one can consume (the body’s satiety often kicks in due to the heavy taste or slight nausea if overconsumed). In any case, kava stands out as a viable natural ethanol alternative with a long track record. Modern research confirms it is an effective anxiolytic (several placebo-controlled trials found kava extracts significantly reduce anxiety) . It is sold as an herbal supplement (e.g. for stress relief), and companies are exploring new formulations. For example, standardized kavalactone capsules and kava beverages are on the market. One challenge is regulatory: in some countries kava is still restricted due to past liver concerns, so regulatory bodies are re-examining data to possibly lift those bans.
Other Herbal or “Botanical” Alternatives
Beyond kava, various herbal concoctions have been used to mimic mild alcohol effects. These typically combine several plant extracts that each contribute a bit of anxiolytic or mood-lifting action. For instance, the product Sentia Red, formulated by GABA Labs (as a stop-gap before Alcarelle), contains a blend of botanicals that enhance GABA transmission . According to GABA Labs, Sentia’s recipe includes ingredients like passionflower, lemon balm, linden, ashwagandha, magnolia bark, and damiana, among others . Many of these are known mild relaxants:
Passionflower contains GABA-modulating flavonoids (chrysin, apigenin) that have anxiolytic effects.
Lemon balm (Melissa officinalis) inhibits GABA transaminase, raising GABA levels, and is calming.
Magnolia (honokiol and magnolol) directly modulate GABA_A receptors (at the benzodiazepine site) and have anxiolytic, anti-stress effects.
Ashwagandha is an adaptogen that may reduce stress hormones and has GABA-mimetic activity.
Damiana has mild euphoric and anxiolytic reputed effects (possibly due to apigenin and other compounds).
Linden flower (Tilia) is a sedative tea in folk medicine.
Hawthorn, Licorice, etc., can have calming cardiovascular and glycyrrhizin-mediated cortisol modulating effects.
Additionally, Sentia includes myrcene, a terpene (found in hops and cannabis) that has sedative properties .
Such botanical mixtures aim to synergistically produce a mellow, convivial mood. Because each ingredient at legal dose levels has only mild effects, combining them can yield a noticeable relaxation without any one component being strong enough to be unsafe . Sentia’s effect has been likened to feeling like you’ve had one glass of wine – a slight “fuzzy” relaxation . This is intentional, as they keep the potency moderate to ensure no ill effects for consumers. The advantage of herbal drinks is that they can often be sold without new regulatory approval if all ingredients are already GRAS or supplement-approved. The disadvantage is that they might not satisfy someone looking for a pronounced alcohol-like buzz.
Other companies (e.g. Kin Euphorics, Psychedelic Water) have their own blends, using things like kava, 5-HTP, L-theanine, CBD, ginseng, etc. to create mood-enhancing beverages. Psychedelic Water, despite the name, is essentially a kava-based drink with damiana and green tea extract – users report mild relaxation/tingling. Kin Euphorics mixes nootropics and botanicals (like Rhodiola, caffeine, 5-HTP, GABA, etc.) to produce a “social energy” without booze. The efficacy of these can vary and often the effects are subtle or reliant on placebo expectation. Nevertheless, they represent a growing market of non-alcoholic functional beverages. These are generally safe (ingredients are at supplement doses) and avoid alcohol’s harms, but they are far less potent than ethanol. For health-conscious individuals who just want a slight mood lift and something to sip, they offer an alternative.
In academic research, efforts are underway to systematically identify more plant-based GABA agonists. As noted by GABA Labs, many plants produce GABA-like molecules as part of their stress physiology . Screening the edible plant kingdom for those that have GABAergic effects (and can cross the blood-brain barrier) is an ongoing project . The combination of mild ingredients plus bioavailability enhancers (like adding piperine from black pepper, or borneol, to increase absorption of actives) has been explored to amplify the impact of herbal formulas . While no herbal mix will ever be as instantly intoxicating as a shot of vodka, these botanical alternatives can be part of the toolkit for individuals seeking to avoid ethanol.
Comparative Summary of Candidate Compounds
The following table summarizes key candidate alcohol replacements, comparing their mechanisms, psychoactive effects, toxicity, and status:
(Table sources: Mechanisms and effects from references as cited in text – e.g., GABA-A PAM effects , GHB effects , pregabalin effects , MEAI effects , kava effects . Toxicity and dependence from cited studies and reviews – e.g., kava hepatotoxicity reviews , benzo/alcohol harm assessments , etc.)
Toxicology Profile Considerations
A key motivator for finding an alcohol replacement is reducing ethanol’s toxicity. As the table illustrates, most candidate compounds do not cause the kind of physical harm ethanol does. Liver toxicity is markedly lower in these alternatives: for instance, none of the GABA-targeting synthetic drugs produce toxic metabolites like acetaldehyde. Neurotoxicity (brain cell damage, cognitive decline) is also expected to be less – alcohol’s neurotoxic effects stem from glutamate excitotoxicity during withdrawal and nutritional deficiencies; compounds like Alcarelle or benzos, if used in moderation, shouldn’t kill neurons or cause dementia (though heavy long-term benzodiazepine use might contribute to cognitive impairment). Addiction potential, however, remains a concern for many of these candidates. Virtually any substance that reliably produces euphoria or anxiety-relief can be habit-forming. As one addiction specialist cautioned, “There’s no free lunch in neurobiology – a euphoric or relaxant effect will have some rebound or dependence risk” . The challenge is to find a molecule that the brain doesn’t easily develop tolerance to. A partial agonist like Alcarelle is one strategy – by capping the effect, it may also cap the brain’s compensatory changes. Additionally, an ideal alternative would not strongly trigger the dopamine-driven reward loop (to avoid reinforcement). Some of the compounds like kava or certain gabapentinoids have relatively low dopamine activation, which might explain a lower craving profile.
In terms of overdose safety, many of these alternatives are safer than alcohol. Alcohol poisoning can be fatal (by respiratory arrest or aspiration). By contrast, pregabalin overdose usually causes deep sleep but not death (unless combined with other depressants) . Benzodiazepine overdose alone is rarely lethal as well (benzos mainly become deadly alongside other CNS depressants). GHB overdose can be fatal due to coma, but it has a short duration (if the person is kept alive and airways protected, they usually recover within hours). MEAI’s overdose profile isn’t fully known, but as a serotonergic, the bigger risk might be hyperthermia or serotonin syndrome rather than respiratory failure. Kava overdose just leads to extreme sedation and possibly nausea – there are no recorded direct fatalities from kava. So, on acute terms, a lot of these are less likely to cause immediate death by overdose than hard liquor.
Another aspect is the long-term health impact. Alcohol contributes to hypertension, cardiomyopathy, immune suppression, and cancer (even one drink a day increases risk of certain cancers). The alternatives largely don’t have evidence of doing this. For example, there’s no indication that kava or gabapentin cause cancer or heart disease. Some (like kava or neurosteroids) might actually have neuroprotective or anti-stress effects biologically . Of course, lack of data means we should be cautious – widespread use of a new synthetic intoxicant might reveal unforeseen issues after many years (as seen with past “wonder drugs”). Thus rigorous testing is crucial.
Current Development and Outlook
Several academic labs and companies are actively pursuing these alternatives:
GABA Labs (UK) – developing Alcarelle; already launched Sentia (herbal) as a precursor step . Team includes neuropharmacologists and chemists aiming to revolutionize social drinking .
Clearmind Medicine (Israel/Canada) – developing MEAI (CMND-100) for alcohol abuse treatment . They hold patents on MEAI and related molecules, and are exploring it for binge behaviors broadly .
Pharmaceutical companies – in the past, big firms like AstraZeneca, Merck, and Lundbeck explored non-sedating anxiolytics (AZD7325, MK-809, Gaboxadol (THIP) etc.). While those programs were not aimed at “recreational” use, the knowledge feeds into what an alcohol alternative might target (e.g. specific GABA_A subtypes). It’s possible a pharma could revive a shelved compound (like a partial GABA modulator) for this new indication if the market demand grows.
Supplement and beverage companies – Numerous startups in the wellness space (Kin Euphorics, Recess, Three Spirit, etc.) are marketing “mood drinks.” While these are more about branding than pharmacology, some are investing in research on novel botanicals and nootropics to include. For instance, companies are looking at whether THC-free cannabis terpenes, or minor cannabinoids, can give relaxation without intoxication; or whether adaptogenic mushrooms (reishi, etc.) can elevate mood subtly. These efforts blur the line between nutrition and pharmacology.
Academic research – Beyond David Nutt’s group, others are studying neuroactive steroids as safer sedatives, oxytocinergic compounds (oxytocin hormone can increase social bonding and is being researched for social anxiety – perhaps an oxytocin nasal spray could mimic some pro-social effects of alcohol without intoxication), and even kappa-opioid antagonists (which can produce antidepressant and pro-social effects by boosting dopamine). There’s also interest in partial agonists of 5-HT2A (psychedelic microdoses) to enhance mood socially – though evidence there is still sparse.
A major hurdle for any new compound intended for recreational use is regulation. If classified as a “food or supplement,” the burden is to show safety (to a reasonable certainty) but not absolute efficacy. If classified as a “drug,” it would need clinical trials and would likely be prescription-only initially. GABA Labs is cleverly aiming for the “novel food” route in the UK/EU and GRAS in US for Alcarelle , meaning they will argue it’s a food additive that’s safe at intended use levels. This still requires rigorous safety data – chronic toxicity tests, etc. Assuming they succeed, we might see non-alcoholic beers spiked with Alcarelle sold freely. If not, Alcarelle might end up a medicine or at least an age-restricted product. Public acceptance is another factor: people are accustomed to ethanol after thousands of years; convincing them a “synthetic alcohol” is safe and fun will take marketing and transparency. Early media has both hyped the idea and cautioned that “it sounds too good to be true” . Ensuring that these new alternatives don’t inadvertently cause new problems (for example, unknown allergenicity, or people mixing them with real alcohol leading to unpredictable effects) will be important.
Conclusion
In conclusion, the landscape of potential alcohol replacements spans from reformulations of known drugs (GABAergics like benzos or GHB in a safer package) to novel psychoactive molecules (Alcarelle, MEAI) and time-honored natural substances (kava, herbs). Each comes with trade-offs. The ideal compound would replicate the positives of ethanol – anxiety reduction, mood lift, social ease – while eliminating the negatives of toxicity and addiction. No candidate is perfect yet, but some come close in certain aspects.
Alcarelle is poised to test whether a targeted GABA_A partial modulator can truly dissociate “the good from the bad” of alcohol . If it lives up to its design, social drinking in the future may involve ordering an “Alcarelle cocktail” that leaves you refreshed the next day with your liver unharmed. Alternatively, a polypharmacy approach might emerge: low doses of a GABAergic + a serotonergic combined (for example, a blend of kava and MEAI) could cover more of alcohol’s subjective spectrum than any single compound.
The next few years will likely see increased R&D in this space, driven by the public’s interest in wellness and the alcohol industry’s recognition that health-conscious consumers want options. Even governmental health bodies are intrigued – reducing alcohol harm via safer substitutes could have big public health gains . Of course, careful testing is needed to ensure these “cure-all” promises pan out and do not create new dependency crises. As of 2025, a true ethanol replacement that is wholly safe and satisfying remains something of a holy grail, but the candidates discussed here show that it is scientifically plausible. In the meantime, those seeking an alternative can already experiment (responsibly) with some of the above: kava drinks, low-dose gabapentinoids (with medical supervision), or upcoming botanical “social tonics.” The bar of the future may have a different menu – one where the question “what’s your poison?” may become a quaint metaphor, since the “drinks” won’t be poisonous at all.
Sources: Key references include Nutt et al. (2022) on functional alcohol alternatives , GABA Labs and media interviews , pharmacology studies on kava , GHB and pregabalin clinical research , and Clearmind’s work on MEAI , among others as cited above. These illustrate the current understanding of each compound’s effects and risks in comparison to ethanol.